+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Topical Skin Infection Treatment Drug Pipeline Analysis Report 2025- Product Image
Topical Skin Infection Treatment Drug Pipeline Analysis Report 2025- Product Image
New

Topical Skin Infection Treatment Drug Pipeline Analysis Report 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102660
Description Jump to:
Skin and soft tissue infections have an incidence of 24.8 cases per 1,000 people. Research reveals that children under the age of 5 and adults over 65 years are more prone to developing a skin infection. As a result, leading pharmaceutical companies are involved in designing a diverse range of drugs that cater to a wide spectrum of affected individuals.

Report Coverage

The Topical Skin Infection TreatmentDrug Pipeline Insight Report by the publisher gives comprehensive insights into topical skin infection treatmentdrugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Topical skin infection treatment. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The topical skin infection treatment pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from topical skin infection treatment.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to topical skin infection treatment.

Topical Skin Infection Treatment Drug Pipeline Outlook

Skin infection can be caused by various types of germs such as bacteria, viruses, fungi and parasites. Common bacterial skin infections include cellulitis, impetigo, and staphylococcal (staph) infections. Shingles, warts and herpes are examples of viral skin infections while yeast infections and athlete's foot are fungal infections. Individuals having poor circulation, diabetes, immune system diseases or obesity are at a higher risk of developing skin infections. Symptoms can include rashes, swelling, redness, pain, pus, and itching.

The treatment for skin infections varies on the type of infection and seriousness. Topical solutions such as creams or lotions are commonly advised by healthcare professionals. In January 2024, the United States FDA approved berdazimer gel 10.3% for the treatment of molluscum contagiosum (MC) in adults. Several drugs are under evaluation to treat and manage various skin infections effectively.

Topical Skin Infection Treatment - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

The pipeline assessment report covers 50+ drug analyses based on drug classes:

  • Antibiotics
  • Antifungals
  • Antivirals
  • Corticosteroids

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.
  • Topical

Topical Skin Infection Treatment - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for topical skin infection treatment. There are around 67 drugs in phase II of topical skin infection treatment drugs.

Topical Skin Infection Treatment - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under topical skin infection treatmentpipeline analysis include antibiotics, antifungals, antivirals, and corticosteroids, among others. The medication depends on the type of infection and its severity. For instance, antibiotics are used to treat bacterial infections while corticosteroids are often used in combination with antimicrobial agents to reduce inflammation.

Topical Skin Infection TreatmentClinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the topical skin infection treatmentdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in topical skin infection treatment clinical trials:
  • GlaxoSmithKline
  • Fraser Health
  • Pfizer
  • Taro Pharmaceuticals USA
  • Medical Life Care Planners, LLC
  • Hoth Therapeutics, Inc.

Topical Skin Infection Treatment- Emerging Drugs Profile

Topical SB-275833 Ointment, 1%

This topical is under investigation to treat impetigo in adults and children. Sponsored by GlaxoSmithKline, the ointment is in a randomised, observer-blind, multicentre, non-inferiority, comparative, Phase III study and is being evaluated for its safety and efficacy.

Retapamulin

Currently, in Phase III of an interventional study, Retapamulin is under evaluation to treat patients with SITL or impetigo due to MRSA (Methicillin-Resistant Staphylococcus Aureus).

AN2690 Topical Solution

Pfizer’s AN2690 Topical Solution is being evaluated to treat onychomycosis of the toenail. The medication is in Phase 3 of a randomized, multi-center study that has around 600 patients.

Topical HT-00

This topical gel, developed by Hoth Therapeutics Inc., is under investigation for the treatment of EGFR inhibitor-induced skin toxicities. As a part of the study, the participants will apply the gel once a day for 6 weeks and will be assessed for its safety and efficacy.

Reasons To Buy This Report

The Topical Skin Infection Treatment Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for topical skin infection treatment. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within topical skin infection treatment pipeline insights.

Key Questions Answered in the Topical Skin Infection Treatment- Pipeline Insight Report

  • What is the current landscape of topical skin infection treatment pipeline drugs?
  • How many companies are developing topical skin infection treatment drugs?
  • How many phase III and phase IV drugs are currently present in topical skin infection treatment pipeline drugs?
  • Which companies/institutions are leading the topical skin infection treatment drug development?
  • What is the efficacy and safety profile of topical skin infection treatment pipeline drugs?
  • What are the opportunities and challenges present in the topical skin infection treatment drug pipeline landscape?
  • Which company is conducting major trials for topical skin infection treatment drugs?
  • What geographies are covered in topical skin infection treatment?
  • What are emerging trends in topical skin infection treatment clinical trials?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Topical Skin Infection Treatment
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Topical Skin Infection Treatment: Epidemiology Snapshot
5.1 Topical Skin Infection Treatment Incidence by Key Markets
5.2 Topical Skin Infection Treatment- Patients Seeking Treatment in Key Markets
6 Topical Skin Infection Treatment: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Topical Skin Infection Treatment: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Topical Skin Infection Treatment, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Topical Skin Infection Treatment Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Topical Skin Infection Treatment Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Amphotericin B in 30% DMSO
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 SB-275833 ointment, 1%
10.2.3 Retpamulin Ointment, 1%
10.2.4 AN2690 Topical Solution, 5%
10.2.5 Other Drugs
11 Topical Skin Infection Treatment Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 HT-001 2% Topical Gel
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Topical Skin Infection Treatment Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 MBN-101
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Topical Skin Infection Treatment Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Topical Skin Infection Treatment, Key Drug Pipeline Companies
14.1 GlaxoSmithKline
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Fraser Health
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Pfizer
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Taro Pharmaceuticals USA
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Medical Life Care Planners, LLC
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Hoth Therapeutics, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Products

Topical Skin Infection Treatment - Pipeline Insight, 2025 - Product Image

Topical Skin Infection Treatment - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Onychomycosis Pipeline Analysis Report 2025 - Product Image

Onychomycosis Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Vitiligo Pipeline Analysis Report - Product Image

Vitiligo Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Post-Surgical Infection Drug Pipeline Analysis Report 2025 - Product Image

Post-Surgical Infection Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Human Papillomavirus (HPV) Drug Pipeline Analysis Report 2025 - Product Image

Human Papillomavirus (HPV) Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.